How Much Does Jatenzo Cost in Oregon in 2026?

Oregon Retail Pricing for Jatenzo in 2026

The average cash-pay price for Jatenzo at Oregon retail pharmacies sits at approximately $900 per month in 2026, matching the manufacturer list price set by Tolmar Pharmaceuticals. This price applies to the standard 30-day supply of oral testosterone undecanoate capsules dosed twice daily.

Cash-pay pricing can vary by $50 to $150 between Oregon pharmacies depending on location and purchasing agreements. Patients filling at independent pharmacies in Portland, Eugene, or Salem may find modest differences compared to chain pharmacies like Walgreens or CVS. The FDA-approved prescribing information for Jatenzo specifies a starting dose of 237 mg twice daily, with titration to 158 mg or 316 mg based on serum testosterone levels [1]. Higher doses require more capsules per month, which can push cash-pay costs above $900.

No FDA-approved generic version of oral testosterone undecanoate exists in the United States as of May 2026. Jatenzo holds patent protections that have discouraged generic entry so far. The FDA Orange Book lists active patents on the formulation's lipid-based self-emulsifying delivery system [2]. Without generic competition, list prices have remained flat since 2023.

How Oregon Insurance Plans Cover Jatenzo

Most major commercial insurers operating in Oregon, including Providence Health Plan, Regence BlueCross BlueShield, Moda Health, and PacificSource, classify Jatenzo as a specialty-tier or non-preferred brand medication. Coverage typically requires prior authorization documenting a confirmed diagnosis of male hypogonadism with two morning serum testosterone levels below 300 ng/dL, consistent with the Endocrine Society 2018 clinical practice guideline threshold [3].

Step therapy is the most common barrier. Insurers generally require a trial of at least one injectable testosterone formulation (testosterone cypionate or enanthate) before approving Jatenzo. The clinical rationale rests on cost: generic testosterone cypionate 200 mg/mL costs $30 to $80 per month, compared to $900 for Jatenzo. A 2020 pharmacoeconomic analysis found that oral testosterone undecanoate carried significantly higher per-patient annual costs versus intramuscular formulations, though it also reduced injection-site adverse events and improved adherence in needle-averse patients [4].

Patients whose prior authorization is approved typically face a specialty copay of $50 to $150 per month, depending on their plan tier. For patients on high-deductible health plans, the full $900 may apply until the deductible is met.

Oregon Medicaid (OHP) Coverage and Prior Authorization

Oregon Medicaid, administered through the Oregon Health Plan (OHP), covers Jatenzo with prior authorization. The Oregon Health Authority Pharmacy and Therapeutics Committee reviews testosterone replacement therapies under the androgen drug class. Approval requires documented hypogonadism confirmed by laboratory values, clinical symptoms, and an identified etiology, aligning with AUA guidelines on testosterone deficiency [5].

OHP prior authorization criteria also mandate step therapy through injectable testosterone unless the prescriber documents a clinical contraindication, such as bleeding disorder, anticoagulant therapy, or severe needle phobia affecting adherence. The Endocrine Society guideline recognizes oral testosterone undecanoate as an appropriate alternative when injection-based therapy is not feasible [3]. Turnaround on OHP prior authorization requests is typically 24 to 72 hours for standard requests and 24 hours for urgent requests.

Once approved, OHP beneficiaries pay $0 to $3 in copays for Jatenzo. Fee-for-service Medicaid and Coordinated Care Organization (CCO) plans across Oregon follow the same formulary criteria, though individual CCOs may apply additional utilization management. Patients denied coverage can file an appeal through the Oregon Health Authority grievance process.

The Tolmar Savings Card: How It Works in Oregon

Tolmar Pharmaceuticals offers a manufacturer savings card that can reduce Jatenzo copays to as low as $0 per month for commercially insured patients. The card covers up to a set dollar amount per prescription fill, with a maximum annual benefit. Eligibility requirements exclude patients covered by any federal or state healthcare program, including Medicare, Medicaid, Tricare, and VA benefits.

Eligible Oregon residents with commercial insurance can enroll through the Tolmar patient support program. The savings card applies at the pharmacy point of sale and stacks on top of insurance benefits. A commercially insured patient with a $75 monthly copay, for example, could see that reduced to $0 after the savings card is applied.

The savings card does not reduce the pharmacy's reimbursement from the insurer; it covers only the patient's out-of-pocket share. Patients paying full cash price (without insurance) may not qualify for the same card but can explore the Tolmar patient assistance program, which provides Jatenzo at no cost to qualifying low-income patients. Income thresholds vary but generally align with 400% of the federal poverty level, a structure similar to other branded testosterone replacement programs.

Compounded Oral Testosterone Undecanoate in Oregon

Oregon permits 503A compounding pharmacies to prepare oral testosterone undecanoate capsules under valid patient-specific prescriptions. This is legal under federal law (FDCA Section 503A) and Oregon Board of Pharmacy regulations, provided the compounding pharmacy holds appropriate state licensure and the prescription is written for an individually identified patient [6].

Compounded oral testosterone undecanoate pricing in Oregon is substantially lower than branded Jatenzo. Cash-pay costs from licensed 503A pharmacies can be significantly reduced compared to the $900 branded price. The compounded product uses the same active pharmaceutical ingredient but may differ in excipients, capsule formulation, and bioavailability characteristics. The Swerdloff et al. registration trial that supported Jatenzo's FDA approval used the specific SEDDS (self-emulsifying drug delivery system) formulation, and its pharmacokinetic data do not directly transfer to compounded versions [7].

Prescribers should be aware that compounded testosterone products are not FDA-approved and do not carry the same regulatory oversight for potency, purity, and stability. The FDA has issued guidance distinguishing between FDA-approved medications and compounded preparations, noting that compounded drugs are not evaluated for safety and efficacy [8]. Patients choosing compounded oral testosterone undecanoate should confirm their pharmacy holds current Oregon Board of Pharmacy licensure and follows USP 795 compounding standards.

Jatenzo via Telehealth in Oregon

Oregon law permits telehealth prescribing of Jatenzo. The Oregon Medical Board allows prescribers to establish a patient-provider relationship through synchronous audio-video telehealth encounters, and testosterone replacement therapy, including Schedule III controlled substances like Jatenzo, can be prescribed through this modality.

The Ryan Haight Act governs telemedicine prescribing of controlled substances at the federal level. Under current DEA policy, prescribers must conduct at least one qualifying telemedicine encounter before prescribing Schedule III substances, and the DEA's 2023 telemedicine rule permits initial prescribing via telemedicine with specific documentation requirements [9]. Oregon-based telehealth platforms and HealthRX offer Jatenzo prescribing with appropriate clinical evaluation, lab confirmation, and follow-up monitoring.

Telehealth visits for testosterone therapy in Oregon typically include baseline labs (total testosterone, free testosterone, LH, FSH, CBC, lipid panel, PSA for men over 40), consistent with the Endocrine Society monitoring recommendations [3]. Follow-up labs are drawn at 3 months and then every 6 to 12 months to assess therapeutic response and monitor hematocrit, which the Jatenzo FDA label flags as a key safety parameter given the drug's associated increase in hematocrit and hemoglobin [1].

Clinical Profile: Why Jatenzo Costs What It Does

Jatenzo's pricing reflects its position as the first FDA-approved oral testosterone replacement therapy in the United States. The Swerdloff et al. key trial (N=166) demonstrated that oral testosterone undecanoate 237 mg twice daily achieved mean steady-state testosterone concentrations of 489 ng/dL, with 87% of patients reaching the eugonadal range of 300 to 1,100 ng/dL at day 90 [7].

The SEDDS formulation technology required to achieve adequate oral bioavailability of testosterone undecanoate is proprietary to Tolmar. Earlier oral testosterone undecanoate formulations available outside the United States (such as Andriol) used a simpler oleic acid vehicle with erratic absorption. Jatenzo's lipid-based matrix significantly improved absorption consistency, as shown in pharmacokinetic studies demonstrating reduced intra-patient variability compared to older formulations [10].

The cardiovascular safety profile remains an important consideration. The FDA's 2015 label update required all testosterone products to carry warnings about possible cardiovascular risk [11]. The TRAVERSE trial (N=5,246), published in the New England Journal of Medicine in 2023, found that testosterone replacement therapy did not increase the incidence of major adverse cardiovascular events compared to placebo in men aged 45 to 80 with hypogonadism and preexisting or high risk for cardiovascular disease [12]. Blood pressure monitoring is specifically recommended for Jatenzo because the FDA label notes dose-dependent increases in systolic blood pressure of 3 to 5 mmHg observed during clinical trials [1].

Comparing Jatenzo to Other Testosterone Options in Oregon

For Oregon patients weighing cost against convenience, the price gap between Jatenzo and injectable testosterone is significant. Generic testosterone cypionate 200 mg/mL (10 mL vial) costs $30 to $80 at Oregon pharmacies. Testosterone gel (AndroGel 1.62%) runs $500 to $700 per month without insurance. Testosterone nasal gel (Natesto) costs approximately $600 to $800 per month. Jatenzo at $900 per month is the most expensive non-implantable option.

A 2019 systematic review comparing testosterone delivery formulations found no significant differences in efficacy for raising serum testosterone levels to the eugonadal range across injectable, transdermal, and oral routes, though each carried distinct adverse-effect profiles [13]. Injectable testosterone produced the most supraphysiologic peaks. Transdermal formulations carried skin-transfer risk. Oral testosterone undecanoate avoided both issues but required twice-daily dosing with a fat-containing meal, as the Jatenzo label specifies that absorption decreases by approximately 50% without food [1].

The American Urological Association recommends selecting testosterone formulation based on patient preference, cost, insurance coverage, and adherence potential rather than efficacy differences alone [5]. For Oregon patients who cannot tolerate injections and whose insurance covers Jatenzo after step therapy, the oral formulation offers measurable adherence advantages. A 2021 claims-based analysis found that patients on oral testosterone undecanoate had a 12-month medication possession ratio of 0.72, compared to 0.58 for intramuscular testosterone, suggesting better real-world adherence [14].

Strategies to Lower Your Jatenzo Cost in Oregon

Oregon patients can take several concrete steps to reduce Jatenzo costs. First, apply for the Tolmar savings card if commercially insured. Second, ask your prescriber to submit prior authorization with documentation of injectable testosterone failure or contraindication. Third, if denied, file a formal appeal; Oregon insurance law requires insurers to provide a clinical rationale and an external review option.

For patients without insurance or with plans that exclude Jatenzo entirely, the Tolmar patient assistance program accepts applications from patients at or below 400% of the federal poverty level. Oregon 503A compounding pharmacies can prepare oral testosterone undecanoate at lower cost, though patients should discuss bioavailability differences with their prescriber. The Oregon Board of Pharmacy maintains a public directory of licensed compounding pharmacies in the state.

Patients enrolled in Oregon Health Plan should confirm their CCO's specific formulary requirements, as some CCOs contract with preferred pharmacies that may offer lower dispensing fees. All OHP-covered prescriptions for Jatenzo carry nominal copays of $0 to $3 after prior authorization approval, making Medicaid the lowest-cost coverage pathway for eligible Oregon residents.